DOI: 10.12890/2021_002860

Skin Rash and Interstitial Pneumonia Can Be a Fatal Combination: A Rare Case of Anti-Melanoma Differentiation-Associated Gene 5 (MDA5)-Associated Interstitial Lung Disease

Authors

  • Giorgia Borio Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Chiara Terracciano Neurology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Federico Buttafava Intensive Care Unit, IRCCS San Matteo di Pavia, Italy
  • Andrea Vercelli Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Laura Pagani Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Chiara Zanzani Intensive Care Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Alessandra Manicardi Intensive Care Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Andrea Magnacavallo Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
  • Erika Poggiali Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy

erikapoggiali2@gmail.com

Keywords

MDA5-associated dermatomyositis, MDA5-associated interstitial lung disease, interstitial pneumonia, dyspnoea

Abstract

We report the case of a 62-year-old male patient fully vaccinated for COVID-19, admitted to our emergency room for persistent fever associated with exertional dyspnoea, skin lesions, diffuse myalgias and arthralgias not responsive to broad-spectrum antibiotic and antiviral therapy, who developed a rapidly progressive refractory to treatment interstitial lung disease due to anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, that required mechanical ventilation and ECMO. Here, we highlight the importance of always considering alternative diagnoses, i.e. viral and autoimmune diseases, including anti-MDA5 antibody screening, when dealing with patients with a skin rash, seronegative polyarthralgias and interstitial pneumonia, or acute respiratory distress syndrome of unknown origin.

View the entire article

Downloads

References

  1. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193–2200.
  2. Gupta R, Kumar S, Gow P, Hsien-Cheng Chang L, Yen L. Anti-MDA5-associated dermatomyositis. Intern Med J 2020;50(4):484–487.
  3. Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 2020;95(1):e70–e78.
  4. Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 2021;41(6):1021–1036.
  5. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011;147:391–398.
  6. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 2018;78(4):776–785.
  7. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 2016;29:662–673.
  8. Gupta L, Muhammed H, Naveen R, Kharbanda R, Gangadharan H, Misra D, et al. Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. Rheumatol Int 2020;40(12):2047–2055.
  9. Tokiyama K, Tagawa H, Yokota E, Nagasawa K, Kusaba T, Tsuda Y, et al. [Two cases of amyopathic dermatomyositis with fatal rapidly progressive interstitial pneumonitis]. Ryumachi 1990;30(3):204–209; discussion 209–211.
  10. Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 2020;72(3):488–498.
  11. Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 2020;59(11):3284–3292.
  12. Mrosak J, Banasiak K, Edelheit B, Lapin C, Tory H, Collins M. Polymyxin-B hemoperfusion as a novel treatment for rapidly progressive interstitial lung disease in a pediatric patient diagnosed with anti-MDA5 juvenile dermatomyositis. J Clin Rheumatol. Epub 2019 Nov 15. doi: 10.1097/RHU.0000000000001191.
  13. Hayashi M, Aoki A, Asakawa K, Sakagami T, Kikuchi T, Takada T. Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep 2017;5(4):e00235.
  14. Mao MM, Xia S, Guo BP, Qian WP, Zheng ZX, Peng XM, et al. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis/dermatomyositis associated ILD. Respir Med 2020;172:105983.
  15. Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007;26:1647–1654.
  16. Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 2018;57:2114–2119.
  17. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 2019;381(3):291–293.
  18. Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 2016;6:33226.
  19. Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, Ruiz-Rodríguez J, Castellvi I, Rodriguez-Nieto M, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020;50(4):776–790.

Published

2021-10-18

Issue

Vol. 8 No. 10 (2021)

How to Cite

1.
Borio G, Terracciano C, Buttafava F, Vercelli A, Pagani L, Zanzani C, et al. Skin Rash and Interstitial Pneumonia Can Be a Fatal Combination: A Rare Case of Anti-Melanoma Differentiation-Associated Gene 5 (MDA5)-Associated Interstitial Lung Disease. EJCRIM [Internet]. 2021 Oct. 18 [cited 2026 Nov. 4];8(10). Available from: https://ejcrim.com/index.php/ejcrim/article/view/2860

Most read articles by the same author(s)